[ad_1]
TARRYTOWN, N.Y., April 1, 2019 / PRNewswire / – Cibinetide, the main compound of Araim Pharmaceuticals, Inc., A clinical-stage biotechnology company, pioneering in the development of the Inborn Repair Receptor (IRR) activator platform technology, has recently been shown to be effective in improving the efficiency of transplant transplantation. endothelial colony forming cells (ECFC) to repair the vascular system of the retina. CEFC is a type of stem cell that can heal and rebuild damaged blood vessels in the retina.
The research presented in a recently published article, O & # 39; Leary et al. Exp Eye Res 2019, sought to evaluate the CEFC as a therapeutic cell therapy in a mouse model of retinal ischemia and the capacity of the cibinetide to improve the effectiveness of this treatment. Cibinetide uses the body's innate immune-mediated repair system to activate tissue repair due to stress or injury. In vitro, cibinetide was able to improve the survival of CEFCs exposed to oxidative stress. In addition, systemic treatment of mice with cibinetide resulted in a decrease in the number of inflammatory mediators, such as IL-1β and TNF-α in the ischemic retina and brain microglia, and reclbadification of CEFs injected into the damaged vessels was significantly improved, repairing the vessels and revascularizing the retina. Alan Stitt, Queen's University, Belfast, United Kingdom, the lead investigator noted, "we found that the ability to significantly suppress stressors in the retinal environment allowed transplanted cells to survive and accommodate targets to be repaired." Clinical value of this cell therapy and has an obvious potential to advance the approach into a viable treatment option for this blinding disease. "
The cibinetide acts by binding to the IRR that expresses itself in response to stress, such as ischemia. Ischemia causes a cascade of inflammatory signals, including cytokine release and cell death. The binding of cibinetide to IRR leads to the activation of several intracellular signaling pathways that reduce inflammation while activating cellular and tissue repair. Effects similar to those presented have been observed in the preservation and repair of burned skin vessels (Bohr et al., PNAS 2013), as well as the ability of cibinetide to enhance islet cell transplantation in patients with diabetic mice (Watanabe et al., Transplantation 2015). .
The retina contains the photodetector neurons located at the back of the eye. It has one of the highest oxygen consumption rates of all body tissues. Ischemia, decrease or lack of blood supply providing oxygen and nutrients can result from vessel blockage on the retina or vascular problems related to diabetes. Progressive retinal ischemia causes upregulation of inflammatory mediators in the eye, leading to abnormal growth of blood vessels out of the retina and / or leakage, two causes of vision loss and blindness if they are not treated. Available treatments include surgery, treatment with ocular steroid injections or anti-VEGF or laser photocoagulation. These treatments may be effective, but often have side effects and do not address the underlying cause of the disease. This emerging treatment modality of administering therapeutic stem cells directly into the eye is under evaluation, with the badumption that they provide neuroprotection and vascular regeneration, thus preventing progression to loss of vision The addition of cibinetide enhances this effect.
About retinal ischemia
Retinal ischemia, defined as a decrease in blood flow to the retina, underlies the pathology of several major retinal diseases, including diabetic retinopathy, retinopathy of prematurity, and retinal vascular occlusive disease. Ischemia causes overproduction of VEGF resulting in increased vessel permeability and neovascularization. Current treatments are anti-VEGF injections in the eye, laser repair and vitrectomy, which are effective but do not treat the underlying ischemia of the retina.
About Araim Pharmaceuticals, Inc.
Araim Pharmaceuticals, Inc. is a private clinical-stage biopharmaceutical company with a library of peptides that activate the body's immune system to repair the damage caused by chronic diseases and slow down the aging process. We focus on providing innovative treatments that slow down, stop and reverse chronic diseases. As part of an extensive preclinical program, Araim 's IRR agonist library demonstrated in a wide range of pathological conditions that it activated the endogenous system in order to reduce the risk of disease. inflammation, stop the spread of the injury and activate healing and regeneration. Cibinetide, our most advanced program, has completed Phase 2 trials on diabetic neuropathy and sarcoid neuropathy with demonstrated nerve regeneration. http://www.araimpharma.com/
View original content download multimedia: http: //www.prnewswire.com/news-releases/en/channel-famous-cars-endothelial-stem-cell-mediated-vascular-regeneration-for-treatment-of-retinal-ischemia-300821512 .html
SOURCE Araim Pharmaceuticals, Inc.
Source link
